一种MTP抑制剂,可以使WHHL子的异位性脂蛋白水平正常化
J R Wetterau1, R E Gregg, T W Harrity
1Department of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA. Wetterau_John_R@msmail.bms.com
Science (New York, N.Y.)
|October 23, 1998
概括
小分子抑制剂向微小甘油三转移蛋白 (MTP) 可以减少异位性脂蛋白. 化合物9在临床前模型中显示出有效性,这表明它有可能治疗人类的高脂血症.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 阿贝塔利波蛋白血症是由微小的甘油三转移蛋白 (MTP) 缺陷引起的,阻止了阿波利波蛋白B-脂蛋白的产生.
- 甲基性脂蛋白有助于心血管疾病.
- 在脂蛋白组合和分泌中,MTP起着至关重要的作用.
研究的目的:
- 研究MTP小分子抑制剂的治疗潜力.
- 开发一种强大的MTP抑制剂,用于治疗具有高异位性脂蛋白的疾病.
主要方法:
- 高通量查确定了最初的MTP抑制剂.
- 指导合成一种非常强大的MTP抑制剂 (化合物9).
- 化合物9的疗效在动物模型和瓦塔纳贝遗传性高脂血症 (WHHL) 子中进行了测试.
主要成果:
- 化合物9在临床前模型中有效抑制了脂蛋白颗粒的产生.
- 血脂蛋白水平在WHHL子中正常化,这是家族高胆固醇血的一个模型.
- 这项研究验证了MTP抑制作为管理异位性脂蛋白的策略.
结论:
- 小分子MTP抑制是一种可行的治疗策略.
- 化合物9在降低人类的异构脂蛋白方面表现有前途.
- 对化合物9或其衍生物的进一步开发可能会导致高脂血症的新疗法.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...